Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

NCT03968848 PHASE1 COMPLETED Results posted

This study is investigate the influence of severe hepatic impairment on the pharmacokinetics of acalabrutinib and its metabolite.

Details

Lead sponsor	Acerta Pharma BV
Phase	PHASE1
Status	COMPLETED
Enrolment	16
Start date	Mon Nov 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Mar 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatic Impairment
• Hepatic Insufficiency
• Healthy Subjects

Interventions

• acalabrutinib

Countries

United States